Expanding Benzoxazole-Based Inosine 5′-Monophosphate Dehydrogenase (IMPDH) Inhibitor Structure–Activity As Potential Antituberculosis Agents
作者:Shibin Chacko、Helena I. M. Boshoff、Vinayak Singh、Davide M. Ferraris、Deviprasad R. Gollapalli、Minjia Zhang、Ann P. Lawson、Michael J. Pepi、Andrzej Joachimiak、Menico Rizzi、Valerie Mizrahi、Gregory D. Cuny、Lizbeth Hedstrom
DOI:10.1021/acs.jmedchem.7b01839
日期:2018.6.14
tuberculosis. Mycobacterium tuberculosis (Mtb) inosine 5′-monophosphate dehydrogenase 2 (MtbIMPDH2) is a promising yet controversial potential target. The inhibition of MtbIMPDH2 blocks the biosynthesis of guanine nucleotides, but high concentrations of guanine can potentially rescue the bacteria. Herein we describe an expansion of the structure–activity relationship (SAR) for the benzoxazole series of
迫切需要新的药物和分子靶点来解决耐药结核病的出现和传播问题。结核分枝杆菌( Mtb ) 肌苷 5'-单磷酸脱氢酶 2 ( Mtb IMPDH2) 是一个有前途但有争议的潜在目标。Mtb IMPDH2的抑制会阻止鸟嘌呤核苷酸的生物合成,但高浓度的鸟嘌呤可能会拯救细菌。在此,我们描述了苯并恶唑系列Mtb IMPDH2 抑制剂的构效关系 (SAR) 的扩展,并证明可以实现≤1 μM 的最小抑制浓度 (MIC)。最有希望的化合物17b的抗菌活性(Q151 ) 源自Mtb IMPDH2的抑制,如条件性敲低和抗性菌株所证明的。重要的是,鸟嘌呤不会改变17b的 MIC ,减轻了对鸟嘌呤补救可以在体内保护Mtb的担忧。这些发现表明Mtb IMPDH2 是结核病的脆弱目标。